Glioblastomas are the most common primary cancer of the brain, with 13,000 new cases being diagnosed each year in the United States. Although it is a fast-moving cancer, doctors know a lot about this type of tumor and are finding ways to fight it. Here are five things you need to know about glioblastomas. 1. … Read more
Multiple myeloma is one of the most compelling examples of a cancer in which research has markedly improved the length and quality of patients’ lives in the last decade. A malignancy of certain white blood cells in the bone marrow known as plasma cells, myeloma is still considered incurable, but treatment advances have significantly improved survival. … Read more
Melanoma, the most severe form of skin cancer, results from an interaction between the genetics of the individual and damage to DNA from external factors. In the case of melanoma, most of the environmental damage is due to exposure to ultraviolet light from the sun. The cancer develops in the pigment-producing cells of the skin … Read more
When you’re 21, the last words you expect to hear are “you have cancer.” But, that was exactly the news I received in 1976 after a routine trip to my college infirmary landed me in Boston Children’s Hospital with Hodgkin lymphoma. Thanks to new treatments developed through clinical trials and a summer undergoing radiation therapy … Read more
Every year, about 4,700 children in the United States are diagnosed with brain cancer – making it the most common solid tumor in children. It is also one of the most difficult cancers to treat. Brain tumors are the leading cause of cancer-related deaths in children under age 10 and the second leading cause of … Read more
Although skin cancer is the most common cancer in the United States, melanoma accounts for less than 2 percent of all skin cancer cases. The disease is the most aggressive form of skin cancer. Melanoma begins in the melanocytes, which are found on the lower part of the epidermis. The disease can occur anywhere on … Read more
Ten years ago researchers at Dana-Farber and in Japan published a study showing that lung cancer patients whose tumors had a malfunctioning version of a protein called Epidermal Growth Factor Receptor (EGFR) responded dramatically to a drug that specifically targets the EGFR protein. The findings launched the era of precision medicine for lung cancer, transforming … Read more
By Tim O’Neill In 2006, my then 33-years-young wife, Kirsten, was diagnosed with Stage III rectal cancer. Her diagnosis was completely unexpected; she was young, a non-smoker and in overall good health. She had chemotherapy and multiple surgeries. Thankfully, we navigated the treatment with an excellent team of healthcare providers, loving family and caring friends. … Read more
Reports of an experimental drug that slowed advanced breast cancer in a clinical trial have stirred excitement at a national research meeting and breathed new life into a cancer-fighting strategy that had seemed to falter. In one study, the drug, palbociclib, doubled the length of time without disease progression in patients with metastatic estrogen receptor-positive breast … Read more
Medically reviewed by Peter C. Enzinger, MD Although it is not a common disease, esophageal cancer affects about 18,000 new patients each year in the United States. Typically, the disease is found more often in men than in women, with men having about a ten-fold higher risk of developing esophageal cancer. “Esophageal and gastric cancers … Read more
Colorectal cancer is the fourth most common cancer in the U.S., with about 143,000 new patients diagnosed last year. But thanks to increased awareness about screenings, the death rate from colorectal cancer has been dropping for more than 20 years. “For the most part, colorectal cancer is a curable and preventable disease,” says Jeffrey Meyerhardt, … Read more
Outcomes are gradually improving for patients who suffer from graft-versus-host disease (GVHD), one of the most serious complications of stem cell transplantation, and researchers are optimistic that further advances may be on the way.
Not long ago, a diagnosis of multiple myeloma — a cancer of the bone marrow — carried with it a very poor prognosis, with median survival estimates of just two to three years. Now, thanks in large part to research and treatment advances at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), this disease is for many … Read more
In prostate cancer – the most common cancer in men aside from skin cancer – scientists are working to answer some of the most basic questions about the disease while developing an array of new treatments. Using the prostate-specific antigen (PSA) blood test, doctors are often able to detect prostate cancer at an early stage. … Read more
NBC News’ Tom Brokaw, 74, revealed this week he has multiple myeloma, a cancer of the bone marrow. The disease, also known as plasma cell myeloma, will be diagnosed in more than 24,000 Americans this year.
Last month, the American Cancer Society (ACS) released “Cancer Statistics, 2014,” their annual estimate of new cancers diagnoses and deaths for the year ahead. The report was heavily focused on adult malignancies—not surprisingly, given that the number of adult cancer patients in the nation is orders of magnitudes greater than that of childhood patients—but did hold a … Read more
Immunotherapy – stimulating the body’s defenses to recognize and destroy disease-causing cells and proteins – was dubbed the “breakthrough of the year” in 2013 by Science magazine. Dana-Farber researchers have contributed many important discoveries over the years about how the immune system works. Now, they are building on these insights to develop immunotherapy against tumors … Read more
As a result of women having regular cervical cancer screenings, incidence and death rates from the disease have decreased by at least 80 percent in the U.S. “Cervical cancer in the U.S. has become less of a frequently diagnosed cancer because of the institution of the Pap smear,” says Ursula Matulonis, MD, medical director of … Read more
Treatments that unleash the body’s own disease-fighting cells against cancer – an approach known as immunotherapy – have been heralded as the “Breakthrough of the Year” by Science magazine.
Approximately 173,000 people in the United States are living with Hodgkin lymphoma, or are in remission. Less common than non-Hodgkin lymphoma, Hodgkin lymphoma (sometimes referred to as Hodgkin’s lymphoma) is a malignancy of B lymphocytes, an important cell in the immune system. This malignant B cell is known as the Reed-Sternberg cell. Arnold Freedman, MD, … Read more